Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction (O-BRIDGE)

February 23, 2022 updated by: Johan Abeloos, AZ Sint-Jan AV
The investigators aim to develop a prospective database in which patient demographics, surgical, dental, prosthetic and QOL parameters collected during consecutive visits within the framework of routine practice, are being registered for each oncological patient eligible for (immediate/delayed) fixed prosthodontic rehabilitation at time of oral cavity reconstruction

Study Overview

Status

Recruiting

Conditions

Detailed Description

The number of patients requiring major ablative surgery in the oral cavity, including partial/radical mandibular or maxillary resection, due to a head and neck carcinoma, osteoradionecrosis (ORN), or medication-related osteonecrosis of the jaw (MRONJ) has not been accurately reported. Surgical reconstruction to restore oral function and aesthetics forms a challenge to maxillofacial surgeons, and greatly impacts patient' quality of life (QOL). Recently, an active collaboration between the surgeons of the Oral and Maxillofacial Surgery Unit and the prosthodontist (LB) of the Department of Dentistry at the General Hospital Saint-John Bruges led to the development of the "Oncology-bridge (O-bridge)" protocol, which offers (immediate/delayed) fixed prosthetic rehabilitation in a minimum of sessions and a strongly reduced two-week treatment time, consequently accelerating patient' improved QOL at a considerably reduced cost.

The investigators aim to develop a prospective database in which patient demographics, surgical, dental, prosthetic and QOL parameters collected during consecutive visits within the framework of routine practice, are being registered for each oncological patient eligible for (immediate/delayed) fixed prosthodontic rehabilitation at time of oral cavity reconstruction This could provide the investigators with more information about potential patient, surgical and prosthetic factors influencing short- and long-term biological and mechanical stability, as well as patient QOL. Moreover, registration of those results could function as a measurement of quality of care, and could be used for sample size calculation for future large prospective trials.

Study Type

Observational

Enrollment (Anticipated)

55

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All consenting patients with a histologically confirmed oncology diagnosis that requires major ablative surgery of the oral cavity, including segmental or total jaw resection, due to head and neck cancer, ORN or MRONJ

Description

Inclusion Criteria:

  • Patients of all ages
  • Patients of all genders
  • Patients with a histologically or clinically confirmed diagnosis of ORN, MRONJ, as classified by Ruggiero et al. (Ruggiero, et al., 2014) or carcinoma located in the oral cavity and jawbone, requiring segmental or total jaw resection
  • Patients eligible for jaw and oral cavity reconstruction combined with immediate/delayed implant loading for fixed prosthetic rehabilitation
  • Patients not eligible for conventional removable prosthetic rehabilitation

Exclusion Criteria:

  • Patients with a clinically confirmed diagnosis of osteonecrosis not related to an oncological diagnosis or treatment
  • Patients with medical contraindications for jaw reconstruction combined with immediate implant loading for fixed prosthetic rehabilitation
  • Patients eligible for conventional removable prosthetic rehabilitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
implant survival rate
Time Frame: within 12 months postoperative
within 12 months postoperative
bone resorption, as evaluated with cone-beam computed tomography
Time Frame: within 12 months postoperative
within 12 months postoperative
prosthesis survival rate
Time Frame: within 12 months postoperative
within 12 months postoperative
implant survival rate
Time Frame: within 60 months postoperative
within 60 months postoperative
bone resorption, as evaluated with cone-beam computed tomography
Time Frame: within 60 months postoperative
within 60 months postoperative
prosthesis survival rate
Time Frame: within 60 months postoperative
within 60 months postoperative

Secondary Outcome Measures

Outcome Measure
Time Frame
Prevalence of oncological patients requiring jaw reconstruction secondary to tumour resection, ORN or MRONJ
Time Frame: within 12 months postoperative
within 12 months postoperative
Potential biologic or mechanical risk factors predictive of undesirable functional or aesthetic outcomes, through regression analysis
Time Frame: within 60 months postoperative
within 60 months postoperative
Patient' quality of life after prosthetic rehabilitation
Time Frame: until a maximum of 60 months follow-up
until a maximum of 60 months follow-up

Other Outcome Measures

Outcome Measure
Time Frame
patient satisfaction, as measured through visual analogue scale
Time Frame: until a maximum of 60 months follow-up
until a maximum of 60 months follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Johan Abeloos, MD, Department of Oral and Maxillofacial Surgery, General Hospital Saint-John Bruges, Bruges, Belgium

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 1, 2027

Study Registration Dates

First Submitted

January 11, 2016

First Submitted That Met QC Criteria

January 19, 2016

First Posted (Estimate)

January 22, 2016

Study Record Updates

Last Update Posted (Actual)

February 28, 2022

Last Update Submitted That Met QC Criteria

February 23, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • B049201525496

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.